These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 26433887

  • 1. The association of high sCD163/sTWEAK ratio with cardiovascular disease in hemodialysis patients.
    Rusu CC, Racasan S, Kacso IM, Ghervan L, Moldovan D, Potra A, Patiu IM, Bondor C, Caprioara MG.
    Int Urol Nephrol; 2015 Dec; 47(12):2023-30. PubMed ID: 26433887
    [Abstract] [Full Text] [Related]

  • 2. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease.
    Urbonaviciene G, Martin-Ventura JL, Lindholt JS, Urbonavicius S, Moreno JA, Egido J, Blanco-Colio LM.
    Atherosclerosis; 2011 Dec; 219(2):892-9. PubMed ID: 21962403
    [Abstract] [Full Text] [Related]

  • 3. Alterations of soluble TWEAK and CD163 concentrations in patients with chronic heart failure.
    Ptaszynska-Kopczynska K, Marcinkiewicz-Siemion M, Lisowska A, Waszkiewicz E, Witkowski M, Jasiewicz M, Miklasz P, Jakim P, Galar B, Musial WJ, Kaminski KA.
    Cytokine; 2016 Apr; 80():7-12. PubMed ID: 26916171
    [Abstract] [Full Text] [Related]

  • 4. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio.
    Moreno JA, Dejouvencel T, Labreuche J, Smadja DM, Dussiot M, Martin-Ventura JL, Egido J, Gaussem P, Emmerich J, Michel JB, Blanco-Colio LM, Meilhac O.
    Arterioscler Thromb Vasc Biol; 2010 Jun; 30(6):1253-62. PubMed ID: 20299688
    [Abstract] [Full Text] [Related]

  • 5. High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis.
    Kowal-Bielecka O, Bielecki M, Guiducci S, Trzcinska-Butkiewicz B, Michalska-Jakubus M, Matucci-Cerinic M, Brzosko M, Krasowska D, Chyczewski L, Kowal K.
    Arthritis Res Ther; 2013 Jun; 15(3):R69. PubMed ID: 23800379
    [Abstract] [Full Text] [Related]

  • 6. Serum sTWEAK concentrations and risk of developing type 2 diabetes in a high cardiovascular risk population: a nested case-control study.
    Díaz-López A, Chacón MR, Bulló M, Maymó-Masip E, Martínez-González MA, Estruch R, Vendrell J, Basora J, Díez-Espino J, Covas MI, Salas-Salvadó J.
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3482-90. PubMed ID: 23760626
    [Abstract] [Full Text] [Related]

  • 7. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease.
    Valdivielso JM, Coll B, Martín-Ventura JL, Moreno JA, Egido J, Fernández E, Blanco-Colio LM.
    J Nephrol; 2013 Aug; 26(6):1105-13. PubMed ID: 23475462
    [Abstract] [Full Text] [Related]

  • 8. Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension.
    Jasiewicz M, Kowal K, Kowal-Bielecka O, Knapp M, Skiepko R, Bodzenta-Lukaszyk A, Sobkowicz B, Musial WJ, Kaminski KA.
    Cytokine; 2014 Mar; 66(1):40-5. PubMed ID: 24548423
    [Abstract] [Full Text] [Related]

  • 9. Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study.
    Llauradó G, González-Clemente JM, Maymó-Masip E, Subías D, Vendrell J, Chacón MR.
    PLoS One; 2012 Mar; 7(8):e43919. PubMed ID: 22937125
    [Abstract] [Full Text] [Related]

  • 10. Serum sCD163 levels are associated with type 2 diabetes mellitus and are influenced by coffee and wine consumption: results of the Di@bet.es study.
    Rojo-Martínez G, Maymó-Masip E, Rodríguez MM, Solano E, Goday A, Soriguer F, Valdés S, Chaves FJ, Delgado E, Colomo N, Hernández P, Vendrell J, Chacón MR.
    PLoS One; 2014 Mar; 9(6):e101250. PubMed ID: 24978196
    [Abstract] [Full Text] [Related]

  • 11. Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.
    Beltrán LM, Muñoz Hernández R, de Pablo Bernal RS, García Morillo JS, Egido J, Noval ML, Ferrando-Martinez S, Blanco-Colio LM, Genebat M, Villar JR, Moreno-Luna R, Moreno JA.
    PLoS One; 2014 Mar; 9(3):e90541. PubMed ID: 24594990
    [Abstract] [Full Text] [Related]

  • 12. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis.
    Moreno JA, Muñoz-García B, Martín-Ventura JL, Madrigal-Matute J, Orbe J, Páramo JA, Ortega L, Egido J, Blanco-Colio LM.
    Atherosclerosis; 2009 Nov; 207(1):103-10. PubMed ID: 19473660
    [Abstract] [Full Text] [Related]

  • 13. Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD.
    Axelsson J, Møller HJ, Witasp A, Qureshi AR, Carrero JJ, Heimbürger O, Bárány P, Alvestrand A, Lindholm B, Moestrup SK, Stenvinkel P.
    Am J Kidney Dis; 2006 Dec; 48(6):916-25. PubMed ID: 17162146
    [Abstract] [Full Text] [Related]

  • 14. The predictive role of sTWEAK levels in pregnant women with first-trimester vaginal bleeding.
    Kasap B, Özel Türkçü Ü, Akbaba E, Sarıyıldız B, Küçük M, Turhan NÖ, Öner G, Özcan A.
    J Matern Fetal Neonatal Med; 2018 Jul; 31(13):1715-1719. PubMed ID: 28462593
    [Abstract] [Full Text] [Related]

  • 15. Soluble CD163 and TWEAK in early pregnancy gestational diabetes and later glucose intolerance.
    Dereke J, Nilsson J, Nilsson C, Strevens H, Landin-Olsson M, Hillman M.
    PLoS One; 2019 Jul; 14(5):e0216728. PubMed ID: 31071174
    [Abstract] [Full Text] [Related]

  • 16. The impact of synbiotic on serum sCD163/sTWEAK, paraoxonase 1, and lipoproteins in patients with chronic heart failure: a randomized, triple-blind, controlled trial.
    Matin SS, Shidfar F, Naderi N, Amin A, Hosseini-Baharanchi FS, Dehnad A.
    Sci Rep; 2024 Aug 18; 14(1):19120. PubMed ID: 39155305
    [Abstract] [Full Text] [Related]

  • 17. Low blood levels of sTWEAK are related to locoregional failure in head and neck cancer.
    Avilés-Jurado FX, Terra X, Gómez D, Flores JC, Raventós A, Maymó-Masip E, León X, Serrano-Gonzalvo V, Vendrell J, Figuerola E, Chacón MR.
    Eur Arch Otorhinolaryngol; 2015 Jul 18; 272(7):1733-41. PubMed ID: 24858806
    [Abstract] [Full Text] [Related]

  • 18. Plasma CXCL10, sCD163 and sCD14 Levels Have Distinct Associations with Antiretroviral Treatment and Cardiovascular Disease Risk Factors.
    Castley A, Williams L, James I, Guelfi G, Berry C, Nolan D.
    PLoS One; 2016 Jul 18; 11(6):e0158169. PubMed ID: 27355513
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of sCD163 and sTWEAK in patients with stable peripheral arterial disease and association with disease severity as well as long-term mortality.
    Mrak D, Zierfuss B, Höbaus C, Herz CT, Pesau G, Schernthaner GH.
    Atherosclerosis; 2021 Jan 18; 317():41-46. PubMed ID: 33378730
    [Abstract] [Full Text] [Related]

  • 20. The metabolic hormone FGF21 is associated with endothelial dysfunction in hemodialysis patients.
    Rusu CC, Racasan S, Kacso IM, Moldovan D, Potra A, Tirinescu D, Budurea C, Orasan R, Patiu IM, Bondor CI, Vladutiu D, Caprioara MG.
    Int Urol Nephrol; 2017 Mar 18; 49(3):517-523. PubMed ID: 27943169
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.